Genzyme, Dana Farber Cancer Institute, Massachusetts General Hospital deal

GENZ received exclusive worldwide diagnostic rights from the hospital and the institute to mutations in the EGFr gene found in patients with non-small cell lung cancer (NSCLC). GENZ plans to develop a...